Azerbaijan, Baku, Jan. 23 / Trend S.Isayev, T. Jafarov/
Iran has announced that it will domestically manufacture the anti-osteoporosis drugs, ISNA reported.
Researchers from the Nasreddin Tusi's Chemical Technology Institute said the Zoledronic acid will now be manufactured in Iran, while earlier it had to be imported into the country.
Zoledronic acid (INN) or zoledronate (marketed by Novartis under the trade names Zometa, Zomera, Aclasta and Reclast) is a bisphosphonate. Zometa is used to prevent skeletal fractures in patients with cancers such as multiple myeloma and prostate cancer, as well as for treating osteoporosis.
The price for import of such drugs is estimated at 500 EU, while in Iran the same domestically made drug will cost around $100. The drug will be manufactured by Iranian scientists.
Iran to manufacture anti-osteoporosis drugs
Iran has announced that it will domestically manufacture the anti-osteoporosis drugs, ISNA reported.
